CAS: 24211-55-0; (S)-Piperidin-3-Ol

相似化合物

475058-41-4 62414-68-0 143900-43-0

上下游产品

3-hydroxypiperazine (S)-5-hydroxypiperidin-2-one (S)-3-hydroxypiperidine-N-carboxylate benzyl ester (5S)-5-(hydroxymethyl)-2-oxo-tetrahydrofuran (S)-1-N-benzyl-3-hydroxypiperidine (S)-3-hydroxypiperidine-N-carboxylate benzyl ester (R,S)-Benidipine (S,S)-Benidipine

📜(5S)-5-(Hydroxymethyl)-2-Oxo-Tetrahydrofuran置于sodium Azide,Dimethyl Sulfide Borane,20% Palladium Hydroxide-Activated Charcoal,氢气,三乙胺体系中,用 四氢呋喃,甲醇,二氯甲烷,N,N-二甲基甲酰胺 用作溶剂,80.0 °C,101.33 Kpa 条件下,反应 39.0H,反应生成S-3-羟基哌啶
参考文献:天然活性(S)-3-羟基哌啶的简明对映选择性合成
标题:天然活性(S)-3-羟基哌啶的简明对映选择性合成
摘要:摘要 从市售原料开始,采用两种催化途径实现了天然产物 (S)-3-羟基哌啶的短而有效的对映选择性合成:(I) 外消旋甲基-3-(环氧乙烷-) 的共催化水解动力学拆分 (Hkr). 2-基)丙酸酯;(II) 脯氨酸催化的 α-氨基氧化,然后以高对映体纯度 (97% Ee) 和高总产率 (38%) 进行 Horner-Wardsworth-Emmons 烯化.图形概要
Doi:10.1080/00397911.2015.1033428

专利信息

专利号:US-2019040070-A1
优先权日:2016-02-09
标 题:Process for the synthesis of stable amorphous ibrutinib
发明人：MAIER THOMAS; KARAPETYAN INNA; ARAKELYAN ALVARD; MARGARYAN TAMARA; SARGSYAN VARDAN; STEPANYAN HEGHINE; ABOVYAN HERMINE; GERBER AESCHBACHER ROMAN; HAFERKAMP SVEN
权利人:AZAD PHARMACEUTICAL INGREDIENTS AG
摘要:Disclosed herein is a new route of synthesis and a new stable amorphous form of ibrutinib. Also disclosed are pharmaceutical compositions, oral dosage forms and the use of the amorphous ibrutinib in the treatment of mantle cell lymphoma or chronic lymphocytic leukemia.

专利号:US-8519168-B2
优先权日:2007-07-03
标 题 :Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
发明人：FU XIAOYONG; GUENTER FRANK BRUNO; KIM-MEADE AGNES S; MATTHEWS KENNETH STANLEY; MAUST MATHEW THOMAS; MCALLISTER TIMOTHY L; WERNE GERALD; WINTERS JASON L; YIN JIANGUO; ZHANG SHUYI
权利人:FU XIAOYONG; GUENTER FRANK BRUNO; KIM-MEADE AGNES S; MATTHEWS KENNETH STANLEY; MAUST MATHEW THOMAS; WERNE GERALD; WINTERS JASON L; YIN JIANGUO; ZHANG SHUYI; MOLOZNIK DAVID J; MERCK SHARP & DOHME
摘要:This application discloses a novel process for the preparation of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds, which have utility, for example, in the treatment of CXC chemokine-mediated diseases, and intermediates useful in the synthesis thereof.

专利号:US-7129357-B2
优先权日:2003-09-15
标题:Synthesis of quinoline 5-carboxamides useful for the preparation of PDE IV inhibitors
发明人：ANDREWS DAVID R; TANG SUHAN; WU WENXUE; KALLINEY SAMI Y; SUDHAKAR ANANTHA; NIELSEN CHRISTOPHER
权利人:SCHERING CORP
摘要:In one embodiment, the present application discloses a process for making the compound of the formula:

专利号:US-9260428-B2
优先权日:2007-03-22
标 题 :Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
发明人：MERGELSBERG INGRID; SCHERER DOMINIK HERMANN; HUTTENLOCH MONIKA ERIKA; TSUI HON-CHUNG; PALIWAL SUNIL; SHIH NENG-YANG
权利人:OPKO HEALTH INC
摘要:This application discloses a process to synthesize 8-({1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-pheny-1.7-diaza-spiro[4.5]decan-2-one comprising reacting a compound of the Formula 27a-sulfonate with zinc in the presence of acetic acid.

专利号:US-9676783-B2
优先权日:2008-10-22
标 题:Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
发明人：HAAS JULIA; ANDREWS STEVEN W; JIANG YUTONG; ZHANG GAN
权利人:ARRAY BIOPHARMA INC
摘要:Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.

专利号:US-9822116-B2
优先权日:2008-09-05
标 题:Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
发明人：WU GEORGE G; WERNE GERALD; FU XIAOYONG; ORR ROBERT K; CHEN FRANK XING; CUI JIAN; SPRAGUE VICTORIA M; ZHANG FUCHENG; XIE JI; ZENG LIANSHENG; CASTELLANOS LOUIS PETER; CHEN YUYIN; POIRIER MARC; MERGELSBERG INGRID
权利人:OPKO HEALTH INC
摘要:This application discloses a novel process to synthesize 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds, which may be used, for example, as NK-1 inhibitor compounds in pharmaceutical preparations, intermediates useful in said process, and processes for preparing said intermediates; also disclosed is a process for removal of metals from N-heterocyclic carbine metal complexes.